ASX - By Stock
|
MSB |
Re:
Pick the Closing Price after FDA approval on that day
|
|
R2r11
|
449 |
190K |
7 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
449
|
190K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
R2r11
|
854 |
431K |
2 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
854
|
431K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - Aug 2020 on
|
|
R2r11
|
2.3K |
905K |
8 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
2.3K
|
905K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
R2r11
|
854 |
431K |
1 |
09/08/20 |
09/08/20 |
ASX - By Stock
|
854
|
431K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
R2r11
|
10K |
3.0M |
2 |
09/08/20 |
09/08/20 |
ASX - By Stock
|
10K
|
3.0M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
R2r11
|
854 |
431K |
4 |
08/08/20 |
08/08/20 |
ASX - By Stock
|
854
|
431K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - Aug 2020 on
|
|
R2r11
|
2.3K |
905K |
3 |
08/08/20 |
08/08/20 |
ASX - By Stock
|
2.3K
|
905K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - Aug 2020 on
|
|
R2r11
|
2.3K |
905K |
2 |
08/08/20 |
08/08/20 |
ASX - By Stock
|
2.3K
|
905K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
R2r11
|
854 |
431K |
4 |
08/08/20 |
08/08/20 |
ASX - By Stock
|
854
|
431K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MESO action tonight
|
|
R2r11
|
3.1K |
1.4M |
1 |
06/08/20 |
06/08/20 |
ASX - By Stock
|
3.1K
|
1.4M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
1 |
06/08/20 |
06/08/20 |
ASX - By Stock
|
23K
|
13M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
R2r11
|
10K |
3.0M |
4 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
10K
|
3.0M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
2 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
11 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
23K
|
13M
|
11
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
8 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
23K
|
13M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
4 |
04/08/20 |
04/08/20 |
ASX - By Stock
|
17K
|
6.7M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - Most exciting 6 months
|
|
R2r11
|
729 |
373K |
2 |
02/08/20 |
02/08/20 |
ASX - By Stock
|
729
|
373K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
1 |
01/08/20 |
01/08/20 |
ASX - By Stock
|
17K
|
6.7M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Tracking Valuations
|
|
R2r11
|
322 |
170K |
5 |
31/07/20 |
31/07/20 |
ASX - By Stock
|
322
|
170K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C
|
|
R2r11
|
248 |
94K |
0 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
248
|
94K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C
|
|
R2r11
|
248 |
94K |
3 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
248
|
94K
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
1 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
23K
|
13M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
R2r11
|
854 |
431K |
6 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
854
|
431K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
R2r11
|
854 |
431K |
5 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
854
|
431K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
R2r11
|
854 |
431K |
5 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
854
|
431K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
R2r11
|
854 |
431K |
2 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
854
|
431K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
R2r11
|
854 |
431K |
1 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
854
|
431K
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
0 |
27/07/20 |
27/07/20 |
ASX - By Stock
|
23K
|
13M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
R2r11
|
10K |
3.0M |
2 |
23/07/20 |
23/07/20 |
ASX - By Stock
|
10K
|
3.0M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
2 |
21/07/20 |
21/07/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
1 |
21/07/20 |
21/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
1 |
14/07/20 |
14/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
9 |
14/07/20 |
14/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
1 |
12/07/20 |
12/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
0 |
12/07/20 |
12/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
1 |
12/07/20 |
12/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
0 |
12/07/20 |
12/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
0 |
12/07/20 |
12/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
R2r11
|
17K |
6.7M |
3 |
11/07/20 |
11/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
2 |
10/07/20 |
10/07/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Other Inflammatory Diseases - Future Potential for MSB
|
|
R2r11
|
11 |
2.8K |
4 |
10/07/20 |
10/07/20 |
ASX - By Stock
|
11
|
2.8K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Other Inflammatory Diseases - Future Potential for MSB
|
|
R2r11
|
11 |
2.8K |
2 |
10/07/20 |
10/07/20 |
ASX - By Stock
|
11
|
2.8K
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
1 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
23K
|
13M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
2 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
3 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
23K
|
13M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
4 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
23K
|
13M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
2 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
7 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
23K
|
13M
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
3 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
23K
|
13M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
R2r11
|
23K |
13M |
1 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
23K
|
13M
|
1
|
|